ProKidney Corp.: Business Overview, Financials & Competitive Analysis
ProKidney Corp. is a clinical-stage biotechnology company that develops a cell therapy platform for the treatment of multiple chronic kidney diseases. The company develops therapies that repair and restore diseased ki...
Cyborg Score thesis
ProKidney offers a buy opportunity due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and...
Read the full analyst-debate transcript →Get the Latest ProKidney Corp. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeProKidney Corp. Overview
Pro stress-test →ProKidney Corp. is a clinical-stage biotechnology company that develops a cell therapy platform for the treatment of multiple chronic kidney diseases. The company develops therapies that repair and restore diseased kidneys using a patient's own cells and may prevent or delay dialysis or transplant.
Strategic Profile
Pro stress-test →Its lead product candidate, rilparencel, is in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. HC Wainwright & Co. initiated coverage with a Buy recommendation, positioning the company as a promising late-stage clinical player targeting a significant unmet medical need in nephrology.
Competitive Landscape
Pro stress-test →ProKidney competes in the clinical-stage cell therapy space. Direct competitors include other autologous cell therapy developers targeting kidney disease, though ProKidney's lead candidate rilparencel appears positioned as a first-mover in this cell therapy indication with strong FDA alignment.
Industry Context
ProKidney Corp. operates in Biotechnology / Cell Therapy / Nephrology.
Key facts
Founded: 2015 · Headquarters: Winston-Salem, North Carolina · Employees: 204 · Revenue: null · Market cap: $0.761B